INTRODUCTION
Hypertrophic (HTSs) and keloid scars are commonly encountered complaints in dermatological practice [1] . These abnormal lesions are clinically challenging to treat and can be a source of significant distress to both patients and providers [2] . Lesions exhibit no gender preference, but principally emerge in younger individuals and ethnicities with darker complexions, such as African Americans, Asians, and Hispanics [1, 3] . An estimated 5-16% of African Americans and Hispanics experience keloid lesions [1] . Additional risk factors include a personal history of proliferative scars, a family history of HTSs or keloids, and inflammation in and around a wound site [4] . There is currently no explanation for the underlying pathogenesis of HTSs and keloids. These lesions may depict an aberrant wound-healing response to external physical trauma and represent an underlying complication of the extracellular matrix remodeling process [3, 5] . Lesions can present anywhere on the skin surface where physical trauma has occurred; however the ear lobes, face, arms, shoulders, back, and chest are the most commonly afflicted anatomic locations.
HTSs and keloids are differentiated clinically by the extent of tissue overgrowth with respect to the boundaries of the original wound [6] . HTSs are white to pink colored and persist along the margins of the original wound [7] . Contrastingly, keloid lesions are deep red to purple and have the capacity to proliferate well beyond the original borders of the wound [3, 5, 8] . Table 1 compares non-hypertrophic and fibroproliferative scars.
Reasons to pursue treatment for HTSs and keloids include aesthetic considerations related to the psychological stress of cosmetic disfigurement or physical complaints including pain and pruritus [9] . Countless pharmacological agents have been investigated as monotherapy or in various combinations for scar therapy such as surgical excision, occlusive dressings, topical and intralesional corticosteroids, interferon, cryosurgery, radiation, pressure therapy, laser therapy, retinoic acid, and silicone gel sheeting [7] .
Recently published studies investigate the value of laser therapy, including the flash-lamp pulsed dye, fractional carbon dioxide laser, copper bromide laser, and UVA1 laser [10] [11] [12] [13] . Despite an array of therapeutic approaches, no single method provides complete benefit. For this reason, the medical care of HTSs and keloids remains clinically challenging, owing to variable efficacies, side effect profiles, and high instances of recurrence [3] . Chemotherapeutic drugs are also utilized as a treatment option for recalcitrant and recurrent HTSs and keloids [14] . Five-fluorouracil (5-FU) is a pyrimidine analog that inhibits the synthesis of deoxyribonucleic acids by irreversibly inhibiting thymidine synthase, which is responsible for converting uridine to thymidine. Without the structural elements of biosynthesis, rapidly proliferating cells such as fibroblasts are halted and scar degradation is 
RESULTS
The preliminary literature search produced 147 citations. After filtering the search according to inclusion criteria, 69 titles and abstracts were screened for relevance. After screening, a total of 21 articles were included in this review. The selected articles include: ten randomized controlled trials, four prospective single-arm trials, four case series, two case report(s), and an expert opinion. Table 2 presents the  treatment regimen and clinical outcomes of   studies  involving  intralesional  5-FU  monotherapy and intralesional 5-FU with adjuvant corticosteroid therapy.
Intralesional 5-FU Monotherapy
Gupta and Kalra treated 24 consecutive patients with 50-150 mg intralesional injections of 50 mg/ml of 5-FU using 1-week injection intervals for a total of 16 injections. Clinical evaluation by a single observer was done at treatment, cessation of treatment, and the follow-up period. Excellent flattening was seen in 33.3% of patients, and more than 70% reoccurrences in patients who were followed up at 3-6 months [17] .
In a similar study, Nanda and Reddy studied the effects of 5-FU in 28 patients with keloids on the chest, shoulder, upper arms, back, and additional locations. Eight patients had previously failed to respond to triamcinolone acetonide (TAC) 40 mg/cc injections every 3 weeks. Weekly intralesional injections of 0.5-2 ml of 50 mg/ml 5-FU per session were administered for no more than 12 weeks. There was good improvement in 71.4% patients and excellent improvement in 7.1% patients.
Follow-up at 24 weeks revealed no recurrences. Adverse effects included pain in 100%, ulceration in 21.4%, and burning in 7.1% of patients [18] . to excellent patient satisfaction scores as compared to those in the TAC group (85% versus 40%, respectively). Greater overall improvement was also appreciated by observer assessment in the 5-FU group. Ninety-five percent of patients in the 5-FU group achieved good to excellent results, whereas only 50% in the TAC group achieved a good to excellent response [35] .
Wilson et al. utilized botulinum toxin to enhance the inhibitory effect on fibroblasts.
Following surgical excision, 80 patients with keloids were injected with intralesional 50 mg/ ml 5-FU with 50 IU/ml botulinum toxin, using a total dose of less than 140 U. All patients were treatment failures with various other methods.
The mean follow-up period was 19.6 months over which only 3.75% experienced recurrence. More than 80% of patients reported significant improvement and 12.5% conveyed at least slight improvement. Complications included pruritus, pain, and residual post-inflammatory hyperpigmentation. One patient experienced partial wound dehiscence during the postoperative period. Eleven patients (13.75%) experienced late widening of the scar, which resulted in corrective surgery at a later date in half [36] .
DISCUSSION
Fibroblasts are imperative constituents of the normal wound-healing processes, of which there is three distinct stages including inflammation, proliferation, and maturation [4] . First, leukocytes and macrophages clean the wound of cellular debris and bacteria to prevent infection. Next, fibroblasts produce collagen, which gives tissue its tensile strength and structure. The wound site fills with granulation tissue, and the margins contract with the mobility of myofibroblasts allowing for epithelization. In the final phase of wound healing, collagen fibers remodel to improve the overall tensile strength [15] . Disruption of this normal-healing process results in the formation of HTSs and keloids [15] .
A number of new strategies have been 96% of patients achieve good to excellent results [2, 5] . Seeing that, the combination of 5-FU and TAC seem to be more effective than either 5-FU or TAC administered alone [5] . well [6] . Such was the experience of Gupta and Kalra, who found a correlation between therapeutic response and keloid age, with keloids of less than or equal to 5-year duration achieving greater flattening than older keloids [17] . The effects of 585-nm PDL therapy on scars is well known in the literature [38] . Lasers target the scar microvasculature by selective photothermolysis, although the exact mechanisms by which it improves proliferative scars are unknown [7] . Very few studies have explored the effects of adjuvant laser radiation in the context of 5-FU and scar treatments, but
those that have have successfully demonstrated positive results [15, 25, 31, 32] . Fitzpatrick was the first to report his experience with 5-FU and PDL therapy and noted the benefits of less scar erythema [15] ; of note, a follow-up study exhibited no superiority in efficacy with the addition of laser therapy [25] . In the same manner, Katz et al. were the first to report successful results of adjuvant therapy with the 1450-diode laser and also reported successful results [32] . The therapeutic benefits of laser therapy with 5-FU on scars likely improve scar texture and erythema [25] , but it is difficult to comment on the exact efficacy of the combination of laser therapy with 5-FU because of the minimal evidence available.
Additional studies are needed to clarify its efficacy with 5-FU, as there is insufficient evidence of this method. 
Safety and Recurrence

Strengths and Limitations
This review is one of the first to provide a comprehensive, head-to-head comparison of 
CONCLUSION
Further studies are needed to better elucidate the fundamental pathophysiology of HTSs and keloids. Greater understanding of these complex mechanisms will permit the development of more specific treatments to target specific pathways. As a whole, 5-FU is an effective remedy for HTSs and keloids if appropriately administered. Information from the data currently published suggests that 5-FU is a useful agent for treatment in monotherapy, but more so in combination with other agents, particularly low-dose corticosteroids [5] .
Physicians should consider the utility of 5-FU therapy as an alternative treatment strategy in patients who have failed conventional treatments and are experiencing, or would like to avoid, the undesirable long-term adverse effects of corticosteroid use [5] .
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